Heidi D Klepin1, Brandelyn N Pitcher2, Karla V Ballman2, Alice B Kornblith2, Arti Hurria2, Eric P Winer2, Clifford Hudis2, Harvey J Cohen2, Hyman B Muss2, Gretchen G Kimmick2. 1. Wake Forest School of Medicine, Winston-Salem; Alliance Statistics and Data Center, Duke University; Duke University Medical Center, Durham; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; Dana Farber Cancer Institute, Boston, MA; City of Hope National Medical Center, Duarte, CA; and Memorial Sloan Kettering Cancer Center, New York, NY hklepin@wakehealth.edu. 2. Wake Forest School of Medicine, Winston-Salem; Alliance Statistics and Data Center, Duke University; Duke University Medical Center, Durham; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; Dana Farber Cancer Institute, Boston, MA; City of Hope National Medical Center, Duarte, CA; and Memorial Sloan Kettering Cancer Center, New York, NY.
Abstract
PURPOSE: We evaluated associations among comorbidity, toxicity, time to relapse (TTR), and overall survival (OS) in older women with early-stage breast cancer receiving adjuvant chemotherapy. METHODS:Cancer and Leukemia Group B 49907 (Alliance) randomly assigned women ≥ 65 years old with stages I-III breast cancer tostandard adjuvant chemotherapy or capecitabine. We reviewed data from 329 women who participated in the quality of life companion study CALGB 70103 and completed the Physical Health Subscale of the Older American Resources and Services Questionnaire. This questionnaire captures data on 14 comorbid conditions and the degree to which each interferes with daily activities. A comorbidity burden score was computed by multiplying the total number of conditions by each condition's level of interference with function. Outcomes were grade 3 to 5 toxicity, TTR, and OS. Logistic regression was used to evaluate associations between comorbidity and toxicity, and Cox proportional hazards models for TTR and survival. RESULTS: Number of comorbidities ranged from 0 to 10 (median 2); the comorbidity burden score ranged from 0 to 25 (median 3). The most common conditions were arthritis (58%) and hypertension (55%). Comorbidity was associated with shorter OS, but not with toxicity or TTR. The hazard of death increased by 18% for each comorbidity (hazard ratio [HR] = 1.18, 95% CI = 1.06 to 1.33) after adjusting for age, tumor size, treatment, node and receptor status. Comorbidity burden score was similarly associated with OS (HR = 1.08; 95% CI, 1.03 to 1.14). CONCLUSIONS: Among older women enrolled onto a clinical trial, comorbidity was associated with shorter OS, but not toxicity or relapse.
RCT Entities:
PURPOSE: We evaluated associations among comorbidity, toxicity, time to relapse (TTR), and overall survival (OS) in older women with early-stage breast cancer receiving adjuvant chemotherapy. METHODS:Cancer and Leukemia Group B 49907 (Alliance) randomly assigned women ≥ 65 years old with stages I-III breast cancer to standard adjuvant chemotherapy or capecitabine. We reviewed data from 329 women who participated in the quality of life companion study CALGB 70103 and completed the Physical Health Subscale of the Older American Resources and Services Questionnaire. This questionnaire captures data on 14 comorbid conditions and the degree to which each interferes with daily activities. A comorbidity burden score was computed by multiplying the total number of conditions by each condition's level of interference with function. Outcomes were grade 3 to 5 toxicity, TTR, and OS. Logistic regression was used to evaluate associations between comorbidity and toxicity, and Cox proportional hazards models for TTR and survival. RESULTS: Number of comorbidities ranged from 0 to 10 (median 2); the comorbidity burden score ranged from 0 to 25 (median 3). The most common conditions were arthritis (58%) and hypertension (55%). Comorbidity was associated with shorter OS, but not with toxicity or TTR. The hazard of death increased by 18% for each comorbidity (hazard ratio [HR] = 1.18, 95% CI = 1.06 to 1.33) after adjusting for age, tumor size, treatment, node and receptor status. Comorbidity burden score was similarly associated with OS (HR = 1.08; 95% CI, 1.03 to 1.14). CONCLUSIONS: Among older women enrolled onto a clinical trial, comorbidity was associated with shorter OS, but not toxicity or relapse.
Authors: Arti Hurria; Kayo Togawa; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Smita Bhatia; Vani Katheria; Shira Klapper; Kurt Hansen; Rupal Ramani; Mark Lachs; F Lennie Wong; William P Tew Journal: J Clin Oncol Date: 2011-08-01 Impact factor: 44.544
Authors: Kimberly S Peairs; Bethany B Barone; Claire F Snyder; Hsin-Chieh Yeh; Kelly B Stein; Rachel L Derr; Frederick L Brancati; Antonio C Wolff Journal: J Clin Oncol Date: 2010-11-29 Impact factor: 44.544
Authors: Kirsten Erickson; Ruth E Patterson; Shirley W Flatt; Loki Natarajan; Barbara A Parker; Dennis D Heath; Gail A Laughlin; Nazmus Saquib; Cheryl L Rock; John P Pierce Journal: J Clin Oncol Date: 2010-11-29 Impact factor: 44.544
Authors: Alice B Kornblith; Lan Lan; Laura Archer; Ann Partridge; Gretchen Kimmick; Clifford Hudis; Eric Winer; Rebecca Casey; Samantha Bennett; Harvey Jay Cohen; Hyman B Muss Journal: J Clin Oncol Date: 2011-02-07 Impact factor: 44.544
Authors: Dejana Braithwaite; C Martin Tammemagi; Dan H Moore; Elissa M Ozanne; Robert A Hiatt; Jeff Belkora; Dee W West; William A Satariano; Michael Liebman; Laura Esserman Journal: Int J Cancer Date: 2009-03-01 Impact factor: 7.396
Authors: Bethany B Barone; Hsin-Chieh Yeh; Claire F Snyder; Kimberly S Peairs; Kelly B Stein; Rachel L Derr; Antonio C Wolff; Frederick L Brancati Journal: JAMA Date: 2008-12-17 Impact factor: 56.272
Authors: Hyman B Muss; Donald A Berry; Constance T Cirrincione; Maria Theodoulou; Ann M Mauer; Alice B Kornblith; Ann H Partridge; Lynn G Dressler; Harvey J Cohen; Heather P Becker; Patricia A Kartcheske; Judith D Wheeler; Edith A Perez; Antonio C Wolff; Julie R Gralow; Harold J Burstein; Ahmad A Mahmood; Gustav Magrinat; Gutav Magrinat; Barbara A Parker; Ronald D Hart; Debjani Grenier; Larry Norton; Clifford A Hudis; Eric P Winer Journal: N Engl J Med Date: 2009-05-14 Impact factor: 91.245
Authors: Young Chandler; Jinani C Jayasekera; Clyde B Schechter; Claudine Isaacs; Christopher J Cadham; Jeanne S Mandelblatt Journal: J Natl Cancer Inst Date: 2020-06-01 Impact factor: 13.506
Authors: C W Wallwiener; A D Hartkopf; E Grabe; M Wallwiener; F-A Taran; T Fehm; S Y Brucker; B Krämer Journal: J Cancer Res Clin Oncol Date: 2016-06-27 Impact factor: 4.553
Authors: Narjust Duma; Sejal M Kothadia; Tariq U Azam; Siddhartha Yadav; Jonas Paludo; Jesus Vera Aguilera; Miguel Gonzalez Velez; Thorvardur Ragnar Halfdanarson; Julian R Molina; Joleen M Hubbard; Ronald S Go; Aaron S Mansfield; Alex A Adjei Journal: Oncologist Date: 2018-11-09
Authors: Hyman B Muss; Mei-Yin C Polley; Donald A Berry; Heshan Liu; Constance T Cirrincione; Maria Theodoulou; Ann M Mauer; Alice B Kornblith; Ann H Partridge; Lynn G Dressler; Harvey J Cohen; Patricia A Kartcheske; Edith A Perez; Antonio C Wolff; Julie R Gralow; Harold J Burstein; Ahmad A Mahmood; Linda M Sutton; Gustav Magrinat; Barbara A Parker; Ronald D Hart; Debjani Grenier; Arti Hurria; Aminah Jatoi; Larry Norton; Clifford A Hudis; Eric P Winer; Lisa Carey Journal: J Clin Oncol Date: 2019-07-24 Impact factor: 44.544
Authors: Ajeet Gajra; Linda McCall; Hyman B Muss; Harvey J Cohen; Aminah Jatoi; Karla V Ballman; Ann H Partridge; Linda Sutton; Barbara A Parker; Gustav Magrinat; Heidi D Klepin; Jacqueline M Lafky; Arti Hurria Journal: J Geriatr Oncol Date: 2018-03-28 Impact factor: 3.599
Authors: Heidi D Klepin; Ellen Ritchie; Brittny Major-Elechi; Jennifer Le-Rademacher; Drew Seisler; Libby Storrick; Ben L Sanford; Guido Marcucci; Weiqiang Zhao; Susan A Geyer; Karla V Ballman; Bayard L Powell; Maria R Baer; Wendy Stock; Harvey Jay Cohen; Richard M Stone; Richard A Larson; Geoffrey L Uy Journal: J Geriatr Oncol Date: 2019-10-24 Impact factor: 3.599